STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for STAAR Surgical Company for the period ended September 29, 2006. The company develops and manufactures visual implants and ophthalmic products, primarily focusing on cataract surgery (IOLs) and refractive surgery (Visian ICL). The company operates as a single segment and sells products in approximately 50 countries.
Key Financial Metrics
| Metric | Three Months Ended Sep 29, 2006 | Nine Months Ended Sep 29, 2006 | Nine Months Ended Sep 30, 2005 |
|---|---|---|---|
| Net Sales | $13.14 million | $41.02 million | $39.24 million |
| Gross Profit | $6.40 million | $19.84 million | $18.26 million |
| Gross Margin | 48.7% | 48.4% | 46.5% |
| Operating Loss | $(2.69) million | $(8.95) million | $(7.29) million |
| Net Loss | $(2.79) million | $(9.37) million | $(7.75) million |
| Loss Per Share (Basic/Diluted) | $(0.11) | $(0.37) | $(0.33) |
| Cash and Equivalents | $8.19 million (Sep 29, 2006) | Decreased $4.52 million from beginning of period | |
| Working Capital | $18.9 million | Current Ratio: 2.5:1 | |
| Accumulated Deficit | $(81.02) million | As of Sep 29, 2006 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12.8% in the third quarter and 4.5% for the nine-month period compared to 2005. This growth was driven by the U.S. launch of the Visian ICL (refractive sales up 184% QoQ) and improved U.S. cataract sales.
- Expense Increases: Operating expenses rose significantly due to the adoption of SFAS 123R (stock-based compensation), increased marketing for the ICL launch, and higher R&D costs for the Toric ICL approval. Marketing and selling expenses increased 20.2% in the quarter.
- Net Loss: While the net loss increased year-over-year for the nine-month period ($9.37M vs $7.75M), the loss per share improved slightly in the quarter ($0.11 vs $0.13) due to share count changes and a reversal of note reserves.
- Unusual Items: A $331,000 reversal of reserves on notes receivable from former directors occurred in the third quarter following a settlement. Additionally, stock-based compensation expense of $1.33 million was recognized for the nine months due to SFAS 123R adoption.
Outlook, Risks, and Management Commentary
- Strategic Focus: Management is prioritizing the U.S. launch of the Visian ICL and securing FDA approval for the Toric ICL (TICL). They aim to reverse the decline in U.S. cataract market share through enhanced R&D and sales efforts.
- Liquidity: The company reported a cash burn of $4.52 million for the nine months. Management believes current cash, credit facilities ($2.8 million available), and option exercises are sufficient to fund operations for the next year, but future profitability is not assured.
- Risks:
- Regulatory: History of FDA compliance issues; success depends on maintaining strict quality systems.
- Market: Competition from multifocal IOLs in the U.S. and doctor strikes/slow-downs in Germany (a key market) impacting cataract sales.
- Financing: Limited access to credit and a history of losses may require additional equity financing, potentially causing dilution.
- Legal: A securities class action lawsuit regarding the Visian ICL was settled for $3.7 million, with $3.6 million covered by insurance. The company's retention was fully accrued in the prior year.
Investor Verification Checklist
- Verify the timeline and progress of FDA approval for the Toric ICL (TICL) in the U.S.
- Monitor the success of the U.S. Visian ICL rollout and surgeon training adoption rates.
- Assess the impact of German doctor strikes on international cataract revenue trends.
- Review the company's ability to meet financial covenants on its credit facilities given the continued operating losses.
- Confirm the status of the "shelf" registration statement for potential future equity or debt offerings.